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Abstract
Background: Human Phosphatidylethanolamine binding protein 1 (hPEBP1) also known as Raf kinase inhibitory protein
(RKIP), affects various cellular processes, and is implicated in metastasis formation and Alzheimer’s disease. Human PEBP1
has also been shown to inhibit the Raf/MEK/ERK pathway. Numerous reports concern various mammalian PEBP1 binding
ligands. However, since PEBP1 proteins from many different species were investigated, drawing general conclusions
regarding human PEBP1 binding properties is rather difficult. Moreover, the binding site of Raf-1 on hPEBP1 is still unknown.
Methods/Findings: In the present study, we investigated human PEBP1 by NMR to determine the binding site of four
different ligands: GTP, FMN, and one Raf-1 peptide in tri-phosphorylated and non-phosphorylated forms. The study was
carried out by NMR in near physiological conditions, allowing for the identification of the binding site and the
determination of the affinity constants KD for different ligands. Native mass spectrometry was used as an alternative method
for measuring KD values.
Conclusions/Significance: Our study demonstrates and/or confirms the binding of hPEBP1 to the four studied ligands. All of
them bind to the same region centered on the conserved ligand-binding pocket of hPEBP1. Although the affinities for GTP
and FMN decrease as pH, salt concentration and temperature increase from pH 6.5/NaCl 0 mM/20uC to pH 7.5/NaCl
100 mM/30uC, both ligands clearly do bind under conditions similar to what is found in cells regarding pH, salt
concentration and temperature. In addition, our work confirms that residues in the vicinity of the pocket rather than those
within the pocket seem to be required for interaction with Raf-1.
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Introduction
Phosphatidylethanolamine binding protein 1 (PEBP1), also
known as Raf kinase inhibitory protein (RKIP), is involved in
several processes in living cells. Its physiological function,
mechanism of action and binding properties have been studied by
using various cells and tissues from human, bovine, rat and mouse.
The main results have revealed that PEBP1/RKIP regulates three
key mammalian signaling pathways, namely Raf/MEK/ERK, NF-
kB and G-protein coupled receptors (GPCR), and is implicated in
signaling [1–3], proliferation [4], differentiation [5], migration [6],
survival [7], and cell apoptosis [8,9]. PEBP1 acts by direct
interaction with the protein kinases involved in the pathways, such
as Raf-1 [1,10], MEK and ERK [11]. The interaction of PEBP1
with these protein kinases leads to their inhibition. As an example,
the phosphorylation of Raf-1 by p21-activated kinase (PAK) and by
Src family kinases, which is required for Raf-1 activity, is prevented
by PEBP1 binding [12]. Bound Raf-1 is then inactive as a MEK
kinase, which deregulates the ERK pathway. Upon phosphoryla-
tion by PKC on Ser153, PEBP1 dissociates from Raf-1 and inhibits
the G-protein-coupled receptor kinase 2 (GRK2), which is a
negative regulator of GPCRs [13,14]. PEBP1 has also been shown
to bind NF-kB inducing the kinase NIK and to inhibit the signaling
mediated by NF-kB which plays a prominent role in apoptosis [2].
More specifically in human, hPEBP1 has been identified as a
metastasis suppressor [15] since hPEBP1 expression is decreased in
metastatic prostate [16,17] and breast [18,19] cancers. Moreover,
hPEBP1 is a cell sensitizer to chemotherapy and immunotherapy
[20]. Finally, hPEBP1 may also be involved in Alzheimer’s disease
[21], infertility [22,23], and diabetes [24].
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protein (PEBP) family, which is a highly conserved group of more
than 400 ubiquitous proteins found in a variety of tissues from a wide
range of organisms (bacteria, yeasts, insects, mammals and plants).
The crystal structures of PEBPs have revealed a remarkably
conserved ligand-binding pocket. X-ray studies for bovine and
human PEBP1s showed that ions such as acetate and o-phosphor-
ylethanolamine (PE) (PDB 1A44; PDB 1B7A) [25], phosphate and o-
phosphotyrosine (PDB 2QYQ) [26], or cacodylate (PDB 1BEH) [27]
couldbind to this conserved pocket. The conservedpocket isthe only
ligand-binding site of PEBP1s identified by X-ray.
Besides crystallographic data, binding studies have been
reported using other techniques. A study by affinity chromatog-
raphy at pH 7.5 revealed that nucleotides could bind to the bovine
brain PEBP (bPEBP), in the decreasing affinity order
FMN.GTP.GDP.GMP.FAD.ATP.NADP.CTP.UTP.
ADP [28]. Interactions of human and bovine PEBP1s with
morphine and morphine derivatives were characterized at pH 6.8
by noncovalent mass spectrometry [29]. Moreover, an NMR study
of rat PEBP1 (rPEBP1) in near physiological conditions (pH, salt
concentration, temperature) showed that the conserved pocket
could accommodate various ligands such as 1,2-dihexanoyl-sn-
glycero-3-phosphoethanolamine (DHPE), dihexanoylphosphatidyl-
serine (DHPS), dihexanoylphosphatidylglycerol (DHPG), and
dihexanoylphosphatidic acid (DHPA) [30]. The screening of a
chemical library by NMR spectroscopy revealed three novel ligands
for rPEBP1 that also bind to the protein pocket [31]. Shemon and
co-workers (2009) were also interested in the interaction of rPEBP1
withlocostatin ((S)-(+)-4-benzyl-3-crotonyl-2-oxazolidinone), since it
is known to be a cell migration inhibitor whose cellular target is
PEBP1 in cell lines from different origins [6]. However, locostatin
itself could not be analyzed by NMR because of its limited solubility
and the fact that it induced protein precipitation [32]. Contrary to
locostatin, its precursor (S)-4-benzyl-2-oxazolidinone was compat-
ible with NMR studies, which indicated a binding to the conserved
pocket of rPEBP1 [32]. Furthermore, interactions between rat,
mouse or human PEBPs and an inhibitor of phosphodiesterase-5
(PDE5) were shown by combining affinity based enrichment
and mass spectrometry [33]. The binding was confirmed by
solution based assays using absorbance, fluorescence and NMR
spectroscopy.
However, some of these studies have emphasized the importance
of both experimental conditions and the species of the PEBP used in
the binding studies. A comparative NMR study at pH 7.4 and 6.0
showed that some ligands of hPEBP1 and bPEBP1 previously
identified did not interact with rPEBP1 at pH 7.4, particularly PE
[30] and the nucleotides GDP and GTP [31]. Furthermore, the
bindingstudyinvolvingPEBPsfromrat,mouseand human(rPEBP2,
mPEBP1, mPEBP2 and hPEBP1) and an inhibitor of PDE5
evidenced different behaviors depending on the species and the
tissues of origin of the protein, in spite of high sequence homologies
and high similarities in the protein tertiary structures [33].
As previously mentioned, PEBP1 from bovine, human or rat is
able to bind small ligands as well as proteins such as the Raf-1,
MEK and ERK kinases [1,11]. Although the mechanism of
PEBP1 binding to Raf-1 remains unknown, several studies have
provided information about the binding region of Raf-1 on the one
hand, and the binding region of PEBP1 on the other hand. Yeung
and co-workers (2000) showed that the binding domains of Raf-1
with rPEBP1 were subdomains I and II, a region of approximately
100 amino acids [10]. More recent studies revealed that the
phosphorylated N-region of Raf-1, encompassing amino acids 331
to 349, was sufficient to bind to rPEBP1 [34,35]. These data are
consistent with rat and human PEBP1s inhibiting Raf-1 by
preventing its phosphorylation at S338 and Y341 [12]. Besides, it
has been shown that binding to Raf-1 requires the integrity of the
rPEBP1 pocket [30,35] and is influenced by rPEBP1 pocket
occupancy by another ligand (DHPE) [30]. Furthermore, the
P74L mutation of the rPEBP1 pocket affects Raf-1 binding, but
not the binding of DHPE to rPEBP1 [30]. Thus, the rPEBP1 lipid
binding site may be distinct from the kinase binding site, and at
least some of the pocket residues may be involved directly or
indirectly in the interaction between rPEBP1 and Raf-1 [31].
Another work did support the idea of an indirect binding of Raf-1
to the PEBP1 pocket. Indeed, in contrast to DHPE, the locostatin
precursor binding to the rPEBP1 pocket was not sufficient to
interfere with Raf-1 binding [32]. The authors suggested that
other residues of rPEBP1 may be critical for Raf-1 binding.
Thus, inspiteofthenumerous papers concerningPEBP1 binding
ligands, one another’s conclusions are not always in agreement. The
works previously mentioned evidenced different binding behaviors
as a function of (i) the species of PEBP1 (mouse, rat or human) [33],
and (ii) the experimental conditions of binding, particularly the pH
value [31]. Moreover, the binding of Raf-1 is complex and the
binding site on PEBP1 is still unknown. In the present study, we
investigated the human PEBP1 by NMR to determine the binding
site of four different molecules: two nucleotides, GTP and FMN,
because of their relatively high affinities for bPEBP1 [28], and a
Raf-1 peptide of 19 amino acids in tri-phosphorylated and non-
phosphorylated forms. The non-phosphorylated peptide
RPRGQRDSSYYWEIEASEV is the minimal region 331–349 of
Raf-1 required for rPEBP1 binding [34]. Three phospho-amino
acids were incorporated at the positions Ser
338/339 and Tyr
341, since
the phosphorylation enhanced the binding to rPEBP1 as studied by
surface plasmon resonance [34]. In order to examine the effects of
experimental conditions such as pH, salt concentration, and
temperature on binding, we investigated hPEBP1 in two sets of
conditions: MES 10 mM pH 6.5 at 20uC, and HEPES 10 mM,
NaCl 100 mM, pH 7.5 at 30uC (near physiological conditions).
NMR titrations were also used to derive the affinity constants KD of
the ligands with hPEBP1. Native mass spectrometry (MS) was used
as an alternative method for measuring KD at pH 7.4/37uC for
GTP and FMN and at pH 7.4/25uC or pH 6.6/20uC for the tri-
phosphorylated Raf-1 peptide.
Results
15N-
1H heteronuclear single quantum coherence (HSQC)
NMR experiment was used to study the interaction between
hPEBP1 and four different ligands under two sets of experimental
conditions. The HSQC spectrum of a protein monitors peptidic
NH groups, giving one signal per amino acid at the level of the
protein backbone. Since the chemical shift is very sensitive to the
environment of the observed nuclei, the binding of the ligand
affects the chemical shifts of both peptidic nitrogen and proton
within the binding area. Hence, the residues involved in a binding
can be determined using HSQC spectra of hPEBP1 in the
presence or absence of a ligand.
Mammalian PEBP1s crystal structures (PDB 2QYQ [26]) have
revealed a remarkably conserved ligand-binding pocket. The
hPEBP1 pocket can be defined by 16 residues at the surface of the
protein: D70, A73, P74, Y81, W84, H86, V107, G108, G110,
P111, P112, H118, Y120, L180, Y181, and L184 (Figure 1).
GTP and FMN do bind to the ligand-binding pocket of
hPEBP1
NMR titration of GTP in MES 10 mM pH 6.5 at 20uC
revealed 34 residues in fast exchange on the NMR time scale
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PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e36187(Figure 2A). Upon titration, the signals of these residues are shifted
in both dimensions in the HSQC 2D plane, and the trajectories of
the signals are linear, as observed for L184 (Figure 2B). This linear
evolution indicates a single binding event [36]. Mapping of the
residues affected by GTP binding on hPEBP1 structure corre-
sponds to the conserved pocket of hPEBP1 (Figure 3A).
The chemical shift perturbations (CSP) values of the 34
perturbed residues were plotted versus the GTP concentration,
and the data were fitted against equation 2 [37], giving a binding
constant for each residue. Fitted titration data are shown in
Figure 2C for six residues. CSP data were normalized to CSPmax
(with the CSPmax estimate obtained from the curve fitting method
used to calculate KD). The plot of normalized CSP (CSP/CSPmax)
versus the GTP concentration revealed a uniform behavior for 30
of the 34 perturbed residues (data not shown). The data of four
residues (V27, G57, Y106, and G110) gave very different values of
KD compared to those calculated from the 30 other residues
perturbed by GTP, and hence, were not considered for the
estimation of the average binding constant of GTP. Among the
four residues excluded for the KD estimation of GTP, (i) two of
them (V27 and G57) were isolated on the protein surface, (ii) one
(Y106) belongs to the binding surface, but is far from the center of
the hPEBP1 pocket, and (iii) the last one’s peak intensity (G110)
was too low to get data of quality. Thus, estimated from 30
perturbed residues, the average binding constant for GTP at
pH 6.5/20uCi sK D=6696140 mM (Table 1).
A total of 67 residues were affected upon FMN titration in MES
10 mM pH 6.5 at 20uC. Most of these residues were in slow
exchange on the NMR time scale (39 residues in red on Figure 3B)
and defined a binding surface centered on the conserved hPEBP1
pocket. 15 residues in fast exchange and 13 residues in
intermediate exchange on the NMR time scale were also observed
(residues in fast exchange in yellow, and residues in intermediate
exchange in orange on Figure 3B). These residues are located in
the outermost region of the binding surface. Since slow exchange
usually indicates a higher affinity compared to fast or intermediate
exchange, the data show that the pocket corresponds to the region
with the greatest affinity for FMN. However, the binding constant
could not be calculated from the intensity data of the residues in
slow exchange because their peak intensities dropped sharply
when the FMN concentration increased. Hence, the affinity was
estimated from CSP data of residues in fast exchange:
KD=1469 mM. This affinity is therefore underestimated.
GTP and FMN do bind to hPEBP1 in near physiological
conditions
Since the experimental conditions can affect the binding
behavior [31], the binding of GTP and FMN was also investigated
under near physiological conditions: HEPES 10 mM pH 7.5,
NaCl 100 mM, at 30uC.
The binding of GTP in near physiological conditions exhibited
the same features as in MES 10 mM pH 6.5, 20uC, that is, the
same binding site and a fast exchange on the NMR time scale.
Among the 34 residues affected at pH6.5/20uC, 26 were also
perturbed at pH 7.5/NaCl 100 mM/30uC. However, the chem-
ical shift perturbations were smaller in near physiological
conditions (,CSP.+2s=0.058 ppm) than at pH 6.5/20uC
(,CSP.+2s=0.087 ppm) (Figure 4). Moreover, the binding
constant measured for GTP at pH 7.5/NaCl 100 mM/30uC was
342561967 mM, which was higher than 6696140 mM at pH 6.5/
20uC (Table 1).
Similarly to the study performed at pH 6.5/20uC, the titration
of FMN in near physiological conditions revealed residues in slow
exchange on the NMR time scale, as well as residues in
intermediate and fast exchange. The data evidenced the conserved
hPEBP1 pocket as the binding surface in both conditions.
Nevertheless, regarding the residues in slow exchange, the loss in
intensity occurred at a higher FMN concentration at pH 7.5/
NaCl 100 mM/30uC than at pH 6.5/20uC (data not shown). The
estimation of KD from CSP data of residues in fast exchange
confirmed a lower affinity in near physiological conditions:
KD=252684 mM at pH 7.5/NaCl 100 mM/30uC versus
KD=1469 mM at pH 6.5/20uC (Table 1).
The formation of hPEBP1-nucleotide complexes was also
monitored by native MS (data not shown). In ammonium
bicarbonate (ABC) 20 mM at pH 7.4 and 37uC, hPEBP1 was
found to bind with GTP and FMN with KD values of 89648 mM
and 564 mM, respectively (Table 1). As in NMR, hPEBP1 showed
a higher affinity for FMN than for GTP. In native MS, KD values
were measured in the absence of NaCl. In contrast, NMR
measurements were performed in the presence of NaCl 100 mM,
leading to a partial screening of electrostatic charges, and
consequently to higher KD values.
The Raf-1 peptide does bind in tri-phosphorylated and
non-phosphorylated forms to the ligand-binding pocket
of hPEBP1
HSQC spectra displayed a total of 73 perturbed residues upon
titration of the tri-phosphorylated Raf-1 peptide in MES 10 mM
pH 6.5 at 20uC: 54 residues in slow exchange, 11 residues in
intermediate exchange, and 8 residues in fast exchange (Figure 3C).
Among these 73 perturbed residues, 11 residues were buried (V27,
V67, L68, T69, D72, S109, V121, W122, V124, V151, and C168)
and three were isolated at the surface of hPEBP1 (Q15, G57, and
L58). Thus, after discrimination, we determined a single binding
surface composed of 59 residues including and surrounding the
conserved pocket. Neither the intensity data of the residues in slow
exchange, nor the CSP data of the residues in fast exchange did
allow us to estimate the affinity of the tri-phosphorylated Raf-1
peptide. Indeed, on the one hand, the peak intensities dropped
sharply when the Raf-1 peptide concentration increased. And, on
the other hand, the plot of CSP versus Raf-1 peptide concentra-
tion revealed no saturation upon titration.
However, the affinity of hPEBP1 for the tri-phosphorylated Raf-
1 peptide was measured by native MS. A KD value of 45612 mM
was obtained in conditions of incubation similar to the conditions
used for NMR, in ammonium acetate at pH 6.6 and 20uC
Figure 1. The hPEBP1 pocket on the X-ray ribbon structure and
on surface representation (PDB 2QYQ). Residues indicated in blue
are D70, A73, Y81, W84, H86, V107, G108, G110, H118, Y120, L180, Y181,
and L184. Prolines 74, 111 and 112, which belong to the hPEBP1 pocket
but are not detected by HSQC spectrum, are indicated in green.
doi:10.1371/journal.pone.0036187.g001
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found, a value close to the KD of 20 mM determined in solution
with rPEBP1 [34]. All these values are within the same order of
magnitude.
For the NMR titration with the non-phosphorylated Raf-1
peptide in MES 10 mM pH 6.5 at 20uC, only 33 residues were
perturbed: 16 residues in slow exchange, 6 residues in intermediate
exchange, and 11 residues in fast exchange (Figure 3D). After
discrimination of the buried residues (V27, V46, D72, and S109)
and those isolated at the surface (Y29), three surface patches were
identified. Two small surfaces were formed by L25-H26-V34-
G166 and W55/D56/G57/L58/V164 on the opposite side of the
conserved pocket of hPEBP1, but were not large enough to be
considered as potential binding surfaces. Besides, 19 perturbed
residues defined a surface centered on the conserved pocket
similarly to the other ligands. It is worth noticing that the
corresponding binding surface was larger for the tri-phosphory-
lated peptide. In addition, comparison of the peak intensities for
Figure 2. Binding of GTP to hPEBP1 at pH 6.5/206C by NMR. (A) Overlay of
1H,
15N HSQC spectra of hPEBP1 270 mM in the absence (black)
and presence (red) of GTP 4 mM. (B) Expansion of the selected HSQC region. Overlay of six HSQC spectra of hPEBP1 270 mM with increasing
concentration of GTP: 0 mM (black), 0.27 mM (green), 0.54 mM (orange), 1 mM (purple), 2 mM (blue), and 4 mM (red). (C) Plot of CSP versus GTP
concentration; data fitted against equation of KD (see M&M) for the 6 residues indicated on Figure 3A.
doi:10.1371/journal.pone.0036187.g002
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revealed that the intensity loss was less severe for the non-
phosphorylated peptide (data not shown). Altogether, these data
suggest a lower affinity of hPEBP1 for the non phosphorylated
Raf-1 peptide compared to the tri-phosphorylated Raf-1 peptide,
in agreement with literature reports [34]. However, we could not
confirm this with a binding constant value. The severe drop of
peak intensities for the residues in slow exchange and the non-
saturation of CSP for the residues in fast exchange upon titration
did not allow us to estimate the KD as mentioned for the tri-
phosphorylated Raf-1 peptide.
One additional difference could be observed between the two
peptides regarding the perturbation of the pocket itself. The
conserved pocket of hPEBP1 is formed by 16 residues at the
Figure 3. Binding site of ligands at hPEBP1 surface at pH 6.5/206C. Mapping of amino acid residues whose HSQC peak is significantly
affected by (A) GTP, (B) FMN, (C) the tri-phosphorylated Raf-1 peptide, and (D) the non-phosphorylated Raf-1 peptide at the surface of hPEBP1 (X-
Ray; PDB 2QYQ). Red=residues in slow exchange; orange=residues in intermediate exchange; yellow=residues in fast exchange. Prolines 74, 111
and 112, which belong to the hPEBP1 pocket but are not detected by HSQC spectrum, are indicated in green. Serine 153 is indicated in cyan as a
reference point. (E) hPEBP1 sequence alignment (accession number P30086) indicating the residues defining the binding surface of GTP, FMN, the tri-
phosphorylated Raf-1 peptide (3P. Raf-1 peptide), and the non-phosphorylated Raf-1 peptide (Raf-1 peptide). The color code is similar to (D).
doi:10.1371/journal.pone.0036187.g003
Table 1. KD values of nucleotides derived from NMR and MS spectrometry.
Compound NMR KD (mM) pH 6.5/206C NMR KD (mM) pH 7.5/NaCl 100 mM/306CM S K D (mM) pH 7.4/376C
GTP 6696140 342561967 89648
FMN 14692 5 2 684 564
doi:10.1371/journal.pone.0036187.t001
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among these 16 residues, hence only 13 residues of the pocket can
be detected by HSQC. Whereas all these 13 residues were
perturbed upon binding of the tri-phosphorylated Raf-1 peptide,
only four of them were affected by the binding of the non-
phosphorylated peptide: three residues (A73, Y81, and G110) were
located on the edge of the pocket, and only G110 was in the
bottom of the pocket.
Discussion
The present study demonstrates and/or confirms the binding of
hPEBP1 to four ligands, two nucleotides and one Raf-1 peptide in
tri-phosphorylated and non-phosphorylated forms. Although the
affinities for GTP and FMN decrease as pH, salt concentration,
and temperature increased from pH 6.5/NaCl 0 mM/20uCt o
pH 7.5/NaCl 100 mM/30uC according to our NMR data, both
ligands clearly do bind under near physiological conditions.
Moreover, all four ligands bind to the same region centered on the
conserved pocket previously identified by X-ray crystallography.
The binding of the two nucleotides
The binding of GTP and FMN was evidenced in two sets of
conditions (MES 10 mM pH 6.5 at 20uC, and HEPES 10 mM,
NaCl 100 mM, pH 7.5 at 30uC) and involved hPEBP1 pocket as
well. However, hPEBP1 shows a higher affinity for FMN than for
GTP, in agreement with literature reports concerning bPEBP1
[28]. Moreover, a higher affinity was observed at pH 6.5/20uC
than at pH 7.5/NaCl 100 mM/30uC for both GTP and FMN
(Table 1). We carried out complementary experiments to
differentiate the effect of the pH alone. Therefore, FMN was
studied in HEPES 10 mM pH 7.5 at 20uC to compare with the
binding study in MES 10 mM pH 6.5 at 20uC. Similar to the data
at pH 6.5, the titration of FMN at pH 7.5 showed a majority of
residues in slow exchange, but also residues in intermediate and
fast exchange. Altogether, the perturbed residues defined the
hPEBP1 pocket as the binding site of FMN at pH 7.5/20uC (data
not shown). The measured affinity indicated no significant effect of
the pH: KD=14611 mM at pH 7.5/20uC (estimation from CSP
data of 9 residues in fast exchange) versus KD=1469 mMa t
pH 6.5/20uC (estimation from CSP data of 14 residues in fast
exchange). Concerning the effect of salt alone, it is important to
note that the presence of NaCl 100 mM induced no change on the
Figure 4. Comparison of GTP binding to hPEBP1 in two conditions. hPEBP1 chemical shift perturbations at GTP saturation concentration for
both tested conditions: GTP 4 mM at pH 6.5/20uC (white), and GTP 6.4 mM at pH 7.5/NaCl 100 mM/30uC (black). CSP values are higher at pH 6.5/
20uC than pH 7.5/NaCl 100 mM/30uC (hPEBP1 270 and 100 mM, respectively).
doi:10.1371/journal.pone.0036187.g004
Figure 5. Binding of the tri-phosphorylated Raf-1 peptide to
hPEBP1 by Mass Spectrometry. (A) ESI mass spectrum of hPEBP1 in
complex with the tri-phosphorylated Raf-1 peptide, deconvoluted from
10+,9 + and 8+ charge states. The complex was formed by incubating
18 mM hPEBP1 with 67.6 mM Raf-1 peptide at 20uCi n2 0m MN H 4OAc,
pH 6.6. (B) MS-measured hPEBP1 bound fraction as a function of the tri-
phosphorylated Raf-1 peptide concentration.
doi:10.1371/journal.pone.0036187.g005
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modification. Since the pH had no significant effect on FMN
binding and no conformational change of the protein was induced
by the presence of NaCl 100 mM, the decrease of nucleotides
affinity in near physiological conditions was likely due to the
temperature rise as a consequence of Van’t Hoff law in chemical
thermodynamics.
The interaction between hPEBP1 and GTP evidenced at
pH 7.5/NaCl 100 mM/30uC was physiologically relevant despite
the high concentrations of GTP used (from 0 to 6.4 mM to get
saturation). Whereas the average concentration of GTP is
0.47 mM in mammalian cells and fluids [38], local concentration
of GTP could be higher, particularly near the plasma membrane
where receptors are coupled with heterotrimeric GTP-binding
proteins. hPEBP1 is known to regulate G protein-coupled receptor
signaling in vivo [39] and several studies have shown that hPEBP1
is associated with the G protein-coupled receptor kinase (GRK)
[40]. In particular, hPEBP1 phosphorylated by PKC binds to
GRK2 (G receptor kinase 2), inhibiting its activity and preventing
receptor internalisation [14]. Thus, the GTP concentrations used
in our experiments were certainly in the same order of magnitude
as the GTP amounts encountered near the plasma membrane of
living cells. Moreover, similar concentrations were used for GTP
and FMN in order to compare the affinities obtained with both
nucleotides.
The evidence of GTP binding to hPEBP1 in near physiological
conditions contrasts with the NMR study of Shemon and co-
workers (2010). These authors observed that GTP did not cause
significant chemical shift perturbations for rPEBP1 at pH 7.4/
NaCl 100 mM/30uC, even at a very high ligand concentration
(130 mM GTP for 75 mM rPEBP1) [31]. Since similar conditions
of pH, salt and temperature and identical NMR techniques were
used in both studies, this result highlights the difference in binding
behavior between the rat and the human PEBP1s in spite of an
83% sequence identity (Figure 6). Dadvar and co-workers (2009)
have also evidenced different binding behaviors between PEBPs
from two species [33]. In spite of an 84% sequence identity, the in
vitro binding of an inhibitor of PDE5 was significantly more
efficient with the mouse PEBP (mPEBP2) than with hPEBP1.
Since PEBP has multiple isoforms in each species, and the number
of isoforms is different from one species to another, it seems
possible that the binding properties of a given PEBP are different
from those of its counterpart in another species. Thus, the results
obtained for one species cannot be generalized to the other.
The binding of the Raf-1 peptide in tri-phosphorylated
and non-phosphorylated forms
hPEBP1 pocket did bind the tri-phosphorylated Raf-1 peptide
(Figure 3C), as previously shown by surface plasmon resonance
[34], or for rPEBP [30,35]. In particular, our data showed that
residues A73 and S75 surrounding P74 as well as residue H86 were
involved in the binding, supporting the study of Granovsky and co-
workers (2009) that showed the effect of the mutations P74L and
H86A in the pocket on the binding of rPEBP1 with Raf-1 kinase.
Besides, although S153 was not perturbed itself, residues K150,
V151, A152 immediately preceding S153 in a-helix H1 of hPEBP1
were affected by the tri-phosphorylated Raf-1 peptide binding. This
could agree with the fact that rPEBP1 dissociates from Raf-1 upon
phosphorylation by PKC on S153 (Figure 3C) [13,14].
Raf-1 peptide binds more tightly when it is phosphorylated, as
previously demonstrated by Park and co-workers [34]. As
expected, the binding site of the non-phosphorylated Raf-1
peptide was centered on the conserved pocket (Figure 3D),
involving residue G110 at the bottom of the pocket. However,
most residues of the pocket were not involved in the binding.
Indeed, residues in the vicinity of the pocket, rather than those
within the pocket, were perturbed and hence, seemed to be
required for interaction with Raf-1, as previously suggested by
Shemon and co-workers (2009, 2010) [31,32].
Since our data demonstrated differences between rat and
human PEBP1s for GTP binding, we investigated the interaction
with the locostatin precursor (S)-4-benzyl-2-oxazolidinone (Sigma
#294640), for which the binding to rPEBP1 has been evidenced
by NMR under near physiological conditions (Tris-HCl 50 mM
pH 7.4, NaCl 100 mM, 30uC). The titration of the locostatin
precursor with hPEBP1 (in HEPES 10 mM pH 7.5, NaCl
100 mM, 30uC) revealed 19 residues in fast exchange on the
NMR time scale (data not shown). Analysis of the CSP values of
these 19 residues provided a binding constant equal to
173619 mM. The mapping of the perturbed residues on the X-
ray structure of hPEBP1 shows that the locostatin precursor binds
to the hPEBP1 pocket as previously shown for rPEBP1 under
similar conditions (no KD value was measured for rPEBP1) [32].
Figure 6. Multiple sequence alignment of human PEBP1 (hPEBP1, accession number P30086), rat PEBP1 (rPEBP1, accession number
P31044) and mouse PEBP2 (mPEBP2, accession number Q8VIN1). The hPEBP1 residues defining the binding surface of GTP at pH 6.5 and
20uC are colored yellow.
doi:10.1371/journal.pone.0036187.g006
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PEBP1 to two nucleotides (GTP and FMN) and a Raf-1 peptide (in
tri-phosphorylated and non-phosphorylated forms) in different
conditions using NMR and mass spectrometry. All ligands bind to
the same region centered on the conserved ligand-binding pocket of
hPEBP1 previously identified by X-ray crystallography. Our work
confirms that residues in the vicinity of the pocket rather than those
within the pocket seem to be required for interaction with Raf-1
[31,32]. TheaffinityconstantsKD wereestimated byNMRtitration
and/or native mass spectrometry. Although the affinities for GTP
and FMN were lower at pH 7.5/NaCl 100 mM/30uC than at
pH 6.5/20uC, both nucleotides clearly did bind under near
physiological conditions. Since no interaction was shown between
the rat PEBP and GTP by NMR in near physiological conditions
[31], our study demonstrates the specific binding behavior of the
human PEBP1 and highlights the importance of the studied species.
In a therapeutic perspective, the choice to study human PEBP1 is a
critical factor in drawing conclusions on human pathologies.
Materials and Methods
Interaction of hPEBP1 was studied with four different ligands:
two nucleotides, GTP and FMN, and a Raf-1 peptide of 19 amino
acids in tri-phosphorylated and non-phosphorylated forms.
Materials
Guanosine triphosphate (GTP), flavin mononucleotide (FMN),
b-mercaptoethanol (BME), and ammonium bicarbonate (ABC)
were purchased from Sigma (St. Louis, MO). Ammonium chloride
15N 98% (
15NH4Cl) was purchased from Cortecnet (Voisins-Le-
Bretonneux, France). Ammonium acetate (NH4OAc) was pur-
chased from Merck (Darmstadt, Germany) and formic acid 90%
(FA) from Fisher (Loughborough, UK). The Raf-1 peptide in tri-
phosphorylated and non-phosphorylated forms was prepared by
conventional solid-phase peptide synthesis using the Fmoc
strategy. Fmoc-Ser(PO(OBzl)OH)-OH and Fmoc-Tyr(PO(OB-
zl)OH)-OH were used as phosphoderivatives. They were obtained
by combining both a manual chain assembly method and an
automated one with a ABI 433A synthesizer (Applied Biosystems).
Details of the synthesis strategy will be described elsewhere. All
solvents and buffers were prepared using 18 MV purified water
(MilliQ reagent grade system, Millipore).
Production and purification of
15N hPEBP1
15N hPEBP1 was produced according to the method described
by Marley [41]. The cDNA coding the human PEBP1 has been
inserted in pET31b plasmid [29]; E. coli BL21 DE3 cells were used
to overexpress hPEBP1. The general protocol is as follows: 2 L of
an E. coli BL21 (DE3, pET31b) overnight preculture were
inoculated into 60 L of LB. Upon reaching OD600 ,0.7, the cells
were pelleted by centrifugation. The cell pellet was resuspended in
15 L of M9 medium with
15NH4Cl 1 g/L, ampicillin
50 mgm L
21, and then incubated to allow the recovery of growth
and the clearance of unlabeled metabolites. After 1 h, protein
expression was induced by addition of isopropyl-1-thio-b-galacto-
side (IPTG) to a final concentration of 1 mM. After a 2–3 h
incubation period, the cells were harvested and frozen at 220uC.
The purification of hPEBP1 was performed according to a two-
step procedure involving two different ion exchange chromatography
columns. The frozen cell pellet was resuspended in water and loaded
into a French Press cell disruptor. The cell lysate was centrifuged at
14,000 g for 20 min at 4uC. The clear supernatant was dialysed
overnight against Tris 20 mM, EDTA 1 mM, BME 1 mM, pH 8.0.
The dialysed cell lysate was loaded onto an anion exchange
chromatography column (Q Sepharose Fast Flow, Amersham) and
eluted with Tris 20 mM, BME 1 mM, pH 8.0. The fractions
containing hPEBP1, identified with 18% SDS-PAGE, were gathered
and dialysed overnight against NaAc 10 mM, BME 1 mM, pH 5.5.
The dialysed sample was loaded onto a cation exchange chroma-
tography column (Sp Sepharose High Performance, Amersham).
hPEBP1 was eluted with a linear gradient 0–1 M NaCl. The
fractions containing the protein were gathered and dialysed against
MES 10 mM, BME 1 mM, pH 6.5. The protein solution was
aliquoted and stored at 4uC. The final protein purity was assessed
according to 18% SDS-PAGE gel and mass spectrometry.
hPEBP1 and nucleotides purification for mass
spectrometry analysis
Non-labeled recombinant hPEBP1 purified as previously
described [29] was used for mass spectrometry analysis. To
prevent Na
+ adduct formation, the commercial GTP and FMN
nucleotides used in native MS were desalted. For this purpose, a
protocol derived from the RNA-desalting procedure of Limbach et
al. (1995) [42] was set up [43].
NMR measurements
The interactions between hPEBP1 100–270 mM and the four
selected ligands were investigated by
15N-
1H heteronuclear single
quantum coherence (HSQC) NMR experiments with a sensitivity
enhancement and gradient selected coherence.
1H,
15N HSQC
spectra were recorded at 20 or 30uC on a Bruker 500 MHz or a
Varian Inova 600 MHz spectrometer. Two experimental sets of
conditions were tested: MES 10 mM pH 6.5 at 20uC, and HEPES
10 mM, NaCl 100 mM pH 7.5 at 30uC.
Although the backbone assignment is available for the human
protein at pH 4/25uC at the BMRB (BMRB 16992) [44], we
performed our own backbone amide assignment of free hPEBP1 at
pH 6.5/25uC (BMRB 18204) using 3D TROSY-based HNCA,
HN(CO)CA, HNCACB, HN(CO)CACB, HNCO and HN(CA)CO
experiments [45].
1Ha n d
15N chemical shifts were assigned for
96.5% of non-prolines residues: all residues except Met1, Val3,
Asp35, Gln45, Lys47 and Lys187 (total residues: 187; non-prolines
residues: 172; assigned residues: 166/172). Measurements were
performed on a Bruker Avance spectrometer 800 MHz equipped
with a cryogenic
1H{
13C/
15N} triple-resonance probe.
NMR titrations
In the simple case of protein-ligand interactions, the free and the
bound states are observed during the titration. The interpretation
of an NMR spectrum, such as an HSQC, depends on the rate of
exchange between the bound and the free forms. Three different
cases can be observed. If the complex rate of dissociation is very
slow, two separate resonances are observed at the positions
corresponding to the chemical shifts characteristic of the two states
(free and bound). During the titration, the intensity of the free
resonance decreases while the bound resonance one appears and
goes up. This regime corresponds to slow chemical exchange on
the NMR time scale. If the complex rate of dissociation is very fast,
only a single resonance is observed, whose position is the average
of the chemical shifts of the two states, weighted by their relative
populations. In this case, Chemical Shift Perturbations (CSP) are
observed, i.e. the chemical shift evolves as the ligand concentration
increases. This regime corresponds to fast exchange on the NMR
time scale, and is typical for weaker affinity complexes. In the
intermediate chemical exchange case, in addition to CSP, complex
changes will affect the line shape that results in the observation of
very broad signals with low intensity.
Ligand Binding Study of Human PEBP1/RKIP
PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e36187In the fast exchange regime, CSP can be measured from
15N-
HSQC spectra using the equation:
CSP~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ ﬃ
(Dd1H)
2z(0:17|Dd15N)
2
q
, ð1Þ
with d being the chemical shift in ppm [37].
A threshold value was estimated in order to determine
significant CSP. In a first step, all the CSP are considered and
the average (,CSP.) plus two times the standard deviation (s)i s
calculated. Then, the highest CSP (CSP$,CSP.+2s) are
removed from the data and new average and new standard
deviation calculated. The operation is repeated until the
convergence is reached. The final value ,CSP.+2s for the
residues not significantly perturbed corresponds to the threshold.
Once the residues involved in the binding were selected, the
experimental data were fitted with the quadratic equation 2 using
SigmaPlot 9.0 in order to obtain the dissociation constant value
(KD):
CSP~
CSPmax
2| P ½  0
L ½  z P ½  0zKD
  
{
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
L ½  z P ½  0zKD
   2{4| P ½  0| L ½ 
q   
,
ð2Þ
where [P]0 and [L] are the total protein and ligand concentrations,
respectively [46]. A KD value was estimated for each residue
involved in the binding, and then an average was calculated.
In the slow exchange regime, intensity ratios I/I0 can be
calculated upon titration with I the peak intensity at a fixed
concentration of ligand and I0 the initial peak intensity. A method
similar to the one explained for CSP was used to discriminate the
significant loss of intensity. The threshold corresponds to the
average of the intensity ratios values (,I/I0.) minus two times the
standard deviation (s) for the residues not significantly perturbed.
Once the significant perturbations were discriminated, the
perturbed residues were taken into account for the determination
of the binding surface when (i) the perturbation reaches saturation
upon titration, (ii) the residues are located at the surface, and (iii)
define a contiguous surface patch [36].
In the case of the slow exchange regime, the binding constant
can rarely be calculated because peak intensities are not measured
with enough accuracy.
Native mass spectrometry
All MS measurements were performed in an ESI-ion trap model
Esquire HCT or Ultra HCT PTM Discovery (Bruker, Bremen,
Germany), or in a maXis ESI-UHR-Qq-TOF (Bruker). Com-
plexes were formed by incubating hPEBP1 with a range of ligand
concentrations in ammonium bicarbonate 20 mM/formic acid
buffer, pH 7.4 at 37uC or in ammonium acetate 20 mM, pH 6.6
at 20uC. After incubation, samples were treated with a Zeba micro
gel filtration device with a 7 kDa cut-off (Thermo Scientific,
Waltham, MA) prior to MS measurement, or analyzed directly in
MS. The KD was determined by measuring the bound protein
fraction by native MS. Details of the development of the native
MS method for KD determination are described in the work of
Jaquillard et al. (in press) [43].
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